Literature DB >> 16174480

Chronic widespread pain and fibromyalgia: Should reports of increased mortality influence management?

Gary J Macfarlane1.   

Abstract

There have been few studies examining whether persons with chronic widespread pain or fibromyalgia are at increased risk for dying prematurely. Among the studies conducted there is little consistency in results. If there is an increased mortality risk, it is of the order of a 30% excess and it may be related to the lifestyle of patients with these symptoms, including lack of exercise. Skilled judgment is required in determining whether reports of new symptoms are likely to indicate underlying new pathology. Studies are currently underway which will determine whether initial observations of an increased mortality risk can be replicated.

Entities:  

Mesh:

Year:  2005        PMID: 16174480     DOI: 10.1007/s11926-005-0017-8

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  19 in total

1.  The natural history of chronic pain in the community: a better prognosis than in the clinic?

Authors:  G J MacFarlane; E Thomas; A C Papageorgiou; J Schollum; P R Croft; A J Silman
Journal:  J Rheumatol       Date:  1996-09       Impact factor: 4.666

Review 2.  Adult growth hormone deficiency in patients with fibromyalgia.

Authors:  Robert M Bennett
Journal:  Curr Rheumatol Rep       Date:  2002-08       Impact factor: 4.592

Review 3.  Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis.

Authors:  Andrew G Renehan; Marcel Zwahlen; Christoph Minder; Sarah T O'Dwyer; Stephen M Shalet; Matthias Egger
Journal:  Lancet       Date:  2004-04-24       Impact factor: 79.321

4.  Chronic pain in a geographically defined general population: studies of differences in age, gender, social class, and pain localization.

Authors:  H I Andersson; G Ejlertsson; I Leden; C Rosenberg
Journal:  Clin J Pain       Date:  1993-09       Impact factor: 3.442

Review 5.  Exercise for treating fibromyalgia syndrome.

Authors:  A Busch; C L Schachter; P M Peloso; C Bombardier
Journal:  Cochrane Database Syst Rev       Date:  2002

6.  Is back pain increasing? Results from national surveys in Finland during 1978/9-1992.

Authors:  P I Leino; M A Berg; P Puska
Journal:  Scand J Rheumatol       Date:  1994       Impact factor: 3.641

7.  The prevalence and characteristics of fibromyalgia in the general population.

Authors:  F Wolfe; K Ross; J Anderson; I J Russell; L Hebert
Journal:  Arthritis Rheum       Date:  1995-01

8.  Pain and subsequent mortality and cancer among women in the Royal College of General Practitioners Oral Contraception Study.

Authors:  Blair H Smith; Alison M Elliott; Philip C Hannaford
Journal:  Br J Gen Pract       Date:  2003-01       Impact factor: 5.386

9.  Chronic widespread pain in the population: a seven year follow up study.

Authors:  A C Papageorgiou; A J Silman; G J Macfarlane
Journal:  Ann Rheum Dis       Date:  2002-12       Impact factor: 19.103

10.  The prevalence of pain and pain interference in a general population of older adults: cross-sectional findings from the North Staffordshire Osteoarthritis Project (NorStOP).

Authors:  Elaine Thomas; George Peat; Lindsey Harris; Ross Wilkie; Peter R Croft
Journal:  Pain       Date:  2004-07       Impact factor: 6.961

View more
  3 in total

1.  [Is the dilemma of fibromyalgia solved by the guideline?].

Authors:  M Mindach
Journal:  Schmerz       Date:  2008-12       Impact factor: 1.107

2.  Complementary and alternative exercise for fibromyalgia: a meta-analysis.

Authors:  Scott David Mist; Kari A Firestone; Kim Dupree Jones
Journal:  J Pain Res       Date:  2013-03-27       Impact factor: 3.133

3.  Effects of Olive Oil Consumption on Cardiovascular Risk Factors in Patients with Fibromyalgia.

Authors:  Alma Rus; Francisco Molina; María Josefa Martínez-Ramírez; María Encarnación Aguilar-Ferrándiz; Ramón Carmona; María Luisa Del Moral
Journal:  Nutrients       Date:  2020-03-27       Impact factor: 5.717

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.